Renaissance Technologies LLC reduced its position in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF – Free Report) by 38.8% during the 2nd quarter, HoldingsChannel reports. The firm owned 22,967 shares of the company’s stock after selling 14,533 shares during the period. Renaissance Technologies LLC’s holdings in bioAffinity Technologies were worth $50,000 at the end of the most recent quarter.
Separately, Ground Swell Capital LLC purchased a new position in bioAffinity Technologies during the 2nd quarter worth $49,000. Institutional investors and hedge funds own 1.64% of the company’s stock.
Wall Street Analyst Weigh In
Separately, Maxim Group assumed coverage on bioAffinity Technologies in a research report on Tuesday, July 23rd. They set a “buy” rating and a $6.00 target price on the stock.
bioAffinity Technologies Stock Performance
Shares of BIAF stock opened at $1.87 on Tuesday. The firm has a market capitalization of $21.80 million, a price-to-earnings ratio of -2.01 and a beta of 2.92. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.15 and a quick ratio of 1.14. The business has a fifty day moving average of $1.76 and a 200 day moving average of $2.13. bioAffinity Technologies, Inc. has a 1 year low of $1.15 and a 1 year high of $3.62.
bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.19) earnings per share (EPS) for the quarter. The firm had revenue of $2.40 million during the quarter. bioAffinity Technologies had a negative return on equity of 172.06% and a negative net margin of 120.76%.
About bioAffinity Technologies
bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.
Featured Stories
- Five stocks we like better than bioAffinity Technologies
- How to Buy Cheap Stocks Step by Step
- Whirlpool’s High Dividend Yield Is Too Good to Pass Up
- Investing in Commodities: What Are They? How to Invest in Them
- Holiday Spending Boom Ahead: 3 BNPL Stocks Poised for Gains
- How to Calculate Inflation Rate
- Boeing: A Perfect Storm of Trouble Is a Loaded Buying Opportunity
Want to see what other hedge funds are holding BIAF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bioAffinity Technologies, Inc. (NASDAQ:BIAF – Free Report).
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
